AdvaMed Urges CMS To Leave MCIT In Place
In a letter to CMS Administrator Chiquita Brooks-LaSure, the industry association argues that repealing MCIT would deny many Americans access to “transformational” medical technologies.
You may also be interested in...
Despite industry efforts to save what it viewed as a boon to breakthrough medical technology, US Medicare has repealed the Medical Coverage for Innovative Technologies (MCIT) rule. In a more favorable move for industry, the agency scrapped a controversial qualifying definition for coverage eligibility.
The Medical Device Manufacturers Association wants the US Medicare agency to come up with a new rule for implementing a coverage pathway for breakthrough devices by June 2022.
A panel of experts in the health care and medical device industries discussed the fate of the Medicare Coverage for Innovative Technology (MCIT) rule during AdvaMed’s annual Medtech Conference.